Eidos Therapeutics is a pioneering biotech company with a mission to swiftly translate breakthrough science into life-changing treatments. Founded in 2013, the company operates in the Biopharma, Biotechnology, and Pharmaceutical industries. Through a distinctive corporate structure, Eidos Therapeutics merges traditional drug development with innovative, genetically targeted therapies aimed at addressing diseases at their core.
The latest milestone for Eidos Therapeutics was a significant $64.00M Series B investment on 05 April 2018, led by a consortium of prominent investors including RA Capital Management, Aisling Capital, Cormorant Asset Management, Perceptive Advisors, Viking Global Investors, Amzak Health Investors, BridgeBio, and Janus Henderson.
By attracting such substantial investments from key players in the financial market, Eidos Therapeutics exhibits strong potential in the biotech sector, making it a compelling prospect for venture capital firms seeking promising opportunities in the field of genetically targeted therapies.
